Pamba H O, Estambale B B, Chunge C N, Donno L
Department of Medical Microbiology, College of Health Sciences, University of Nairobi, Kenya.
Eur J Clin Pharmacol. 1990;39(4):353-7. doi: 10.1007/BF00315409.
417 patients suffering from intestinal amoebiasis were randomly allocated to 6 different treatment groups in a controlled study in 3 District Hospitals in Kenya. The patients received either aminosidine (A), etophamide (E), nimorazole (N), or the combinations NA, NE, EA. Treatment in all cases was given twice daily for 5 days. Before and after treatment, rectosigmoidoscopy was done in each patient, and stool examination with characterization of invasive (IF) and non invasive (NIF) forms of amoeba was done daily throughout treatment, and on Days 15, 30 and 60 of follow-up. Clinical cure was good after all the treatments, varying from 90 to 100%; parasitological cure at the end of treatment was 100% in the NA and EA treatments groups, and 98% in A group. The incidence of relapses was nil in the EA group, followed by 3% in NA and 6% in A groups. Anatomical cure (healing of ulcers) was 97.8% in the NA group, 95.5% in the N group and 88.5% in the A group. Drug tolerance was excellent or good after all the treatments, except that the EA combination produced diarrhoea in 76.5% of patients. Overall analysis of the findings, including tolerance of the various treatments, showed that aminosidine either alone or in combination with nimorazole gave the best results. Ulcers seen on rectosigmoidoscopy were more common in patients excreting invasive forms of amoebae in their stools.
在肯尼亚的3家地区医院进行的一项对照研究中,417名肠道阿米巴病患者被随机分配到6个不同的治疗组。患者接受了氨苯苷(A)、依托酰胺(E)、硝唑咪(N),或NA、NE、EA组合治疗。所有病例均每日给药2次,持续5天。治疗前后,对每位患者进行直肠乙状结肠镜检查,并在整个治疗期间以及随访的第15、30和60天每天进行粪便检查,以区分阿米巴的侵袭性(IF)和非侵袭性(NIF)形态。所有治疗后的临床治愈率良好,从90%到100%不等;治疗结束时,NA和EA治疗组的寄生虫学治愈率为100%,A组为98%。EA组的复发率为零,其次是NA组的3%和A组的6%。NA组的解剖学治愈率(溃疡愈合)为97.8%,N组为95.5%,A组为88.5%。除EA组合使76.5%的患者出现腹泻外,所有治疗后的药物耐受性均为优良。对研究结果的总体分析,包括各种治疗的耐受性,表明氨苯苷单独使用或与硝唑咪联合使用效果最佳。直肠乙状结肠镜检查发现的溃疡在粪便中排出侵袭性阿米巴的患者中更为常见。